Call Us for Support
+91 9654860915
Finding access to medicine unapproved in your home country can feel overwhelming. We’re here to help you navigate the process, from your initial request to procurement coordination.
Submit your details and prescription to get started.Register today to get started on your medicine access journey.
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Order Unituxin on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
United Therapeutics Corporation
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Unituxin (dinutuximab) is an antibody infusion for children with high-risk neuroblastoma, a cancer of immature nerve cells that mostly affects young children. In the United States it is approved, together with GM-CSF, interleukin-2 (IL-2) and 13-cis-retinoic acid, for children who have had at least a partial response to first-line treatment (chemotherapy, surgery, high-dose chemotherapy with stem cell transplant, and radiation).
It is used as the maintenance (immunotherapy) phase to lower the chance of the cancer coming back. It is given in hospital by a paediatric oncology team. See our oncology medicines.
Neuroblastoma cells carry a fat-sugar molecule called GD2 on their surface. Unituxin is a monoclonal antibody that sticks to GD2 and calls in the immune system to destroy those cells. Some normal nerve cells also carry GD2, which explains the nerve pain this medicine causes.
In the main randomised study, 226 children with high-risk neuroblastoma who had finished first-line treatment received either Unituxin-based immunotherapy plus 13-cis-retinoic acid (113 children) or 13-cis-retinoic acid alone (113 children).
The dose is 17.5 mg/m² of body surface area per day, given as a slow drip over 10 to 20 hours on 4 days in a row, for up to 5 cycles. Cycles 1, 3 and 5 last 24 days and cycles 2 and 4 last 32 days. Before every infusion the child receives fluids, strong pain relief (an intravenous opioid such as morphine, continued until 2 hours after the infusion), an antihistamine and paracetamol. The treating team follows the full schedule in the prescribing information.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Serious and potentially life-threatening infusion reactions occurred in 26% of children. Signs include swelling of the face and airway, breathing difficulty, wheezing, hives and low blood pressure, usually during or within 24 hours of the infusion. Unituxin is given only in a hospital that can treat these reactions straight away.
Pain is very common: 85% of children had pain despite morphine, and it was severe in 51%. It is usually tummy, back, limb or joint pain during the infusion. Severe nerve damage affecting feeling (2% to 9%) and movement has also been reported.
Report blurred vision, a large pupil that reacts slowly to light, or difficulty passing urine. Rarely, inflammation of the spinal cord (transverse myelitis) and a brain swelling syndrome (RPLS) have occurred.
Fluid can leak from blood vessels, causing swelling and low blood pressure. The child is given fluids before each infusion and watched closely.
Serious infections, low blood counts and low sodium, potassium and calcium are common, so blood tests are done often. Treatment is paused during a serious infection. A rare kidney and blood condition called atypical haemolytic uraemic syndrome has also been reported.
For young women of child-bearing age, effective contraception is needed during treatment and for 2 months after the last dose. Breastfeeding should stop during treatment.
Fever, vomiting, diarrhoea, hives, low albumin and raised liver enzymes were also common. This is not a complete list.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Unituxin is not sold in India, so it is imported for one named child at a time. Each cycle uses four infusion days, so we plan the supply cycle by cycle with the paediatric oncology team.
Send the prescription with the child's height and weight (to work out body surface area), the cycle schedule and the start date. Each vial holds 17.5 mg, so a child with a body surface area of 0.6 m² needs about 10.5 mg a day, which is one vial per day, or four vials per cycle. Our pharmacist confirms the count.
A registered pharmacist checks the prescription, the neuroblastoma diagnosis, the summary of first-line treatment and the parent's and child's ID, and tells you at once if anything is missing.
The Unituxin price in India is quoted for the vials needed per cycle, plus cold-chain freight and customs clearance.
We prepare the Form 12A application to CDSCO under Rule 36 of the Drugs and Cosmetics Rules. CDSCO states the Form 12B permit is usually issued within one to two days and stays valid for six months.
The vials travel at 2°C to 8°C in their original cartons, with a temperature logger in every box.
We deliver to the hospital pharmacy before day 1 of the cycle, so the four infusion days are not delayed.
The permit step usually takes one to two working days once all documents are complete. We share the expected delivery date with the quote, as it depends on stock at source and the flight route.
No. Unituxin (dinutuximab) has no marketing approval in India and is not sold in Indian pharmacies. We checked the published minutes of CDSCO's oncology and haematology expert committees from 2018 to November 2026, and dinutuximab does not appear in them. Its European authorisation was withdrawn in 2017, so supply comes from the United States. It can still be imported legally for a named patient under Rule 36, with a Form 12A application and a Form 12B permit.
Unituxin comes as a 17.5 mg/5 mL single-dose vial. The number of vials depends on the child's body surface area: a child with a body surface area up to 1 m² needs one vial a day, and a larger child needs two. The dinutuximab price per cycle therefore depends on the child's size.
No. It is a hospital-only medicine and cannot be sold off the shelf. The legal way is to send the prescription to NPP, and we arrange the permit and import in the patient's name.
Families from Nepal, Bangladesh, Bhutan, Sri Lanka and the Gulf can also ask us, subject to each country's import rules. Read our guide to Indian import regulations for the full legal process.
Unituxin is made by United Therapeutics in the United States. As a Unituxin supplier in India under the named patient route, NPP buys it only through authorised channels and only after the patient's permit is issued, so every vial can be traced to one patient and one prescription.
Unopened vials must be kept in a refrigerator at 2°C to 8°C in the outer carton to protect them from light, and must not be frozen or shaken. We ship in validated insulated boxes with a data logger and check the temperature record on arrival. Read more about our temperature-controlled shipping.
The hospital pharmacy dilutes the dose in a 100 mL saline bag. Per the US label, the diluted bag is kept in the fridge, the infusion must start within 4 hours of preparation, and any bag not used within 24 hours is discarded. A new bag is prepared each infusion day, which is why we deliver the whole cycle's vials before day 1.
A registered pharmacist matches every order with the prescription and the permit before it leaves New Delhi.
For the Unituxin cost in India and current availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Unituxin is given only in paediatric oncology units that can manage infusion reactions and continuous pain relief, so we deliver to the treating hospital.
See how we arrange delivery of imported medicines to hospitals across India.
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message